Nucleic acid-based therapies have been demonstrated to be capable of targeting genetic blueprints in order to enable treatment of a range of disease indications. Over the years, an increasing number of nucleic acid-based therapies have received regulatory approval, highlighting the therapeutic potential and growing popularity of this class of therapeutics. Consequently, this has created increased demand for vectors, which can effectively deliver such therapies. In this context, it is important to note that, conventionally, the production of such therapies was primarily dependent on viral vectors. However, despite the remarkable success in research and development of viral vectors, there are still certain limitations associated with their use. The challenges in use of viral vectors can be attributed to the complications related to immunogenicity and cytotoxicity, cost-intensive development process, and quantity of genetic material, which can be transported in a single run. To mitigate these concerns, innovators are switching to non-viral gene delivery vehicles for the purpose of transfection. Non-viral transfection refers to the targeted delivery of genetic material into a wide variety of cells, using non-viral vectors as the preferred type of carriers. In order to support the growing demand for nucleic acid-based therapies, novel non-viral transfection reagents and systems, which are deemed to be highly suitable for in vitro intracellular delivery, are being developed. Further, considering the growing demand for non-viral vectors and prevalent trends associated with reagents and systems, we believe that this market is likely to witness a steady growth over the coming years.
Key Market Insights
The Non-Viral Transfection Reagents and Systems Market (2nd Edition) - Distribution by Type of Non-Viral Transfection Method (Chemical Methods and Physical Methods), End-User (Academic and Research Institutions, Pharmaceutical Companies and Other End-Users), Application Area (Clinical Applications and Research Applications) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and future opportunity for the players involved in the development of non-viral transfection reagents and systems. The report answers many key questions related to this domain.
Growing Demand for Non-Viral Transfection Reagents and Systems
Non-viral transfection, owing to its multiple benefits, has emerged as a promising alternative for conventional transfection approaches. Advantages offered by this technique include shorter transfection timelines, higher biological efficiency, reduced toxicity levels and versatile nucleic acid delivery. It is worth highlighting that non-viral transfection reagents and systems are anticipated to become a reliable and powerful tool for artificial introduction of genetic materials. At present, several innovator companies are engaged in the development of transfection reagents and systems.
Current Market Landscape of Non-Viral Transfection Reagent and System Developers
The market landscape of non-viral transfection reagent and system developers features a mix of close to 100 large, mid-sized and small companies, which have the required expertise to offer various reagents and systems for non-viral transfection, across different scales of operation. Of these, close to 60 companies have the ability to develop over 185 transfection reagents and transfection kits, that can be used for delivery of genetic materials (DNA, RNA, nucleic acids and proteins). It is worth mentioning that more than 50% of the companies offer lipid-based carrier transfection reagents (e.g. lipid nanoparticles). Moreover, majority of the transfection reagents are being used for delivery of DNA.
Market Size of Non-Viral Transfection Reagents and Systems Market
Driven by the rising interest in research and development activities and the growing demand for non-viral transfection-based products, the non-viral transfection reagents and systems market is anticipated to witness a noteworthy growth in the foreseen future. Specifically, in terms of type of product, the market is anticipated to be driven by non-viral chemical transfection. Further, in the near future, close to 70% of the market is anticipated to be occupied by the players based in North America and Europe.
Who are the Key Players in the Non-Viral Transfection Reagents and Systems Market
Examples of players engaged in this domain (which have also been captured in this report) include Altogen Biosystems, Bio-Rad Laboratories, BEX, BTX (A subsidiary of Harvard Bioscience), Imunon (Formerly known as Celsion), Genprex, Inovio Pharmaceuticals, MaxCyte, MilliporeSigma, Nepa Gene, OZ Biosciences and Thermo Fisher Scientific.
Scope of the Report
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments:
The study presents an in-depth analysis, across different geographies, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:
- An executive summary of the insights captured during our research. It offers a high-level view on the current state of non-viral transfection reagents and systems market and its likely evolution in the mid-long term.
- A general overview of non-viral transfection reagents and systems, highlighting details on transfection methods and its applications, such as advanced therapy medicinal product development, gene silencing, bioproduction of therapeutic protein and stem cell engineering. It also provides information on the different methods of transfection (viral and non-viral), types of viral vectors (AAV, adenoviral, lentiviral, retroviral and others), along with details on chemical methods (lipoplexes, polyplexes, lipoplexes and others) and physical methods (electroporation, gene gun, sonoporation, magnetofection and others) of transfection.
- A detailed assessment of the overall market landscape of the companies developing non-viral transfection reagents, based on several relevant parameters, such as type of carrier used (lipid-based carrier, polymer-based carrier, protein-based carrier, nanotechnology-based carrier, calcium phosphate-based carrier and minicircle-based carrier), compatible cell type (human cell, monkey cell, murine cell and other cell), type of molecule delivered (DNA and RNA), and serum compatibility (serum free and serum compatibility). It also features information on the non-viral transfection reagent developers, highlighting the year of establishment, company size and location of headquarters.
- A detailed assessment of the overall market landscape of the companies developing electroporation-based non-viral transfection systems. The relevant parameters used for the assessment include, compatible cell type (human mammalian cells and other mammalian cells) and type of molecule delivered (DNA and RNA). It also features information on the electroporation transfection systems developers, highlighting the year of establishment, company size and location of headquarters.
- A detailed assessment of the overall market landscape of the companies developing other non-viral transfection systems. The relevant parameters used for the assessment include, compatible cell type (human mammalian cells and other mammalian cells) and type of molecule delivered (DNA and RNA). It also features information on the other non-viral transfection systems developers, highlighting the year of establishment, company size and location of headquarters.
- An in-depth company competitiveness analysis of non-viral transfection reagent and system developers based in North America, Europe and Asia-Pacific. The analysis compares various developers based on developer strength (in terms of years of experience and company size) and product portfolio strength (type of carrier used, compatible cell type, type of molecule delivered and serum compatibility).
- A detailed technology competitiveness analysis of electroporation transfection systems and other non-viral transfection systems, taking into consideration the developer strength (based on the year of establishment and company size of developer) and product portfolio strength (in terms of compatible cell type and type of molecule delivered).
- Tabulated profiles of key players engaged in the development of non-viral transfection reagents and systems (shortlisted based on the type of carrier used, compatible cell type, type of molecule delivered and serum compatibility). Each profile includes a brief overview of the company, financial information (if available), recent developments and an informed future outlook.
- An in-depth analysis of over 80 cell (including TCR and CAR-T cell) and gene therapy developers that are likely to partner with non-viral transfection reagent and system developers, based on several relevant parameters, such as pipeline maturity (which takes into account the phase of development), developer strength (in terms of number of employees), pipeline strength (based on the number of non-viral transfection reagents in pipeline), and type of therapy.
- A review of the various non-viral focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated in 2021), featuring various insightful representations, based on year of initiative, type of initiative (in terms of collaborations and funding), type of therapy (in terms of cell and gene therapies) and target therapeutic area.
- An in-depth analysis of close to 870 patents that have been filed / granted related to non-viral transfection systems, since 2019, highlighting key trends associated with these patents, across type of patent, publication year, application year, geography, type of applicant, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed). In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
- A detailed analysis of more than 450 peer-reviewed, scientific articles focused on non-viral transfection reagents and systems that have been published since 2015, based on year of publication, type of publication, type of molecule delivered, target therapeutic area, key focus areas, popular cells and cell lines. The chapter also highlights the leading publishers across different geographies, key journals (in terms of number of articles published).
- An insightful framework to understand the pricing strategy of the non-viral transfection reagents offered by a company, along with its competitive position in the market. In addition, it presents the equation devised to calculate the likely price of non-viral transfection reagents based upon their characteristics.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as annual number of transfections, share of non-viral systems within the transfections market, cost per transfection and expected annual growth rate across various geographies, we have provided an informed estimates of the likely evolution of the market in the mid to long term, for the period 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of non-viral transfection method (chemical method, and physical method), end-user (academic and research institutions, pharmaceutical companies and other end-users), application area (clinical applications and research applications) and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.
The opinions and insights presented in the report were influenced by discussions held with stakeholders in this domain. The report features detailed transcript of interview held with the industry stakeholders.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Frequently Asked Questions
Question 1: How is the research and development (R&D) activity evolving in the non-viral transfection reagents and systems domain?
Answer: Presently, the non-viral transfection reagents and systems market represents one of the fastest expanding segments of the biopharmaceutical domain. The increasing number of patents (~870 patents in past four years) and publications (~455 publications in past seven years) focused on non-viral vectors demonstrate the continued innovation being carried out in this domain.
Question 2: How many companies offer non-viral transfection reagents and systems?
Answer: At present, close to 100 companies have the required capabilities to offer non-viral transfection reagents and systems across different scales of operation. Further, several developers are entering into strategic alliances in order to consolidate their presence in this field and enhance their existing capabilities related to non-viral transfection systems.
Question 3: What are the different types of initiatives being undertaken by big pharma players for the manufacturing of non-viral transfection reagents and systems?
Answer: More than 10 big pharma players have undertaken several collaborative initiatives related to various transfection reagents and systems. 70% of the collaborations inked by big pharma players in this domain have been focused on research and development.
Question 4: Which segment is likely to have the largest share in the non-viral transfection reagents and systems market?
Answer: Presently, chemical-based transfection method dominates the non-viral transfection reagents and systems market. However, the market is anticipated to be driven by electroporation-based transfection methods, in the foreseen future.
Question 5: How is the non-viral transfection reagents and systems market likely to evolve in the coming years?
Answer: The non-viral transfection reagents and systems market is projected to grow at a CAGR of ~10% in the coming years. Currently, in terms of end-user, the market is likely to be driven by research institutions, followed by pharmaceutical companies. Specifically, in terms of geographical regions, the non-viral transfection reagents and systems market in Europe is anticipated to grow at a relatively faster pace (~13%), in the long term.
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
1. PREFACE
1.1. Chapter Overview
1.2. Key Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Transfection
3.3. Methods of Transfection
3.3.1. Viral Transfection Systems
3.3.1.1. Types of Viral Transfection Vectors
3.3.1.1.1. Adeno-associated Virus-based Vectors
3.3.1.1.2. Adenovirus-based Vectors
3.3.1.1.3. Herpes Virus-based Vectors
3.3.1.1.4. Lentivirus-based Vectors
3.3.1.1.5. Retroviral-based Vectors
3.3.2. Non-Viral Transfection Systems
3.3.2.1. Chemical-based Transfection
3.3.2.1.1. Lipoplexes-based Transfection
3.3.2.1.2. Polyplexes-based Transfection
3.3.2.1.3. Lipo-polyplexes-based Transfection
3.3.2.1.4. Dendrimer-based Transfection
3.3.2.1.5. Cell Penetrating Peptide-based Transfection
3.3.2.2. Physical Transfection Systems
3.3.2.2.1. Electroporation-based Transfection
3.3.2.2.2. Gene Gun-based Transfection
3.3.2.2.3. Sonoporation-based Transfection
3.3.2.2.4. Microinjection-based Transfection
3.3.2.2.5. Magnetofection-based Transfection
3.4. Applications of Transfection
3.4.1. Advanced Therapeutic Medicinal Product Development
3.4.2. Gene Silencing
3.4.3. Generation of Stable Cell Lines
3.4.4. Large-scale Protein Production
3.4.5. Stem Cell Engineering
3.5. Future Perspectives
4. NON-VIRAL TRANSFECTION REAGENTS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. List of Non-Viral Transfection Reagents
4.2.1. Analysis by Type of Carrier Used
4.2.2. Analysis by Compatible Cell Type
4.2.3. Analysis by Type of Molecule Delivered
4.2.4. Analysis by Serum Compatibility
4.3 List of Non-Viral Transfection Reagent Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters (Region-wise)
4.3.4. Analysis by Location of Headquarters (Country-wise)
5. ELECTROPORATION-BASED TRANSFECTION SYSTEMS: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. List of Electroporation-based Transfection Systems
5.2.1. Analysis by Compatible Cell Type
5.2.2. Analysis by Type of Molecule Delivered
5.3. List of Electroporation-based Transfection System Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters (Region -wise)
5.3.4. Analysis by Location of Headquarters (Country-wise)
6. OTHER NON-VIRAL TRANSFECTION SYSTEMS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. List of Other Non-Viral Transfection Systems
6.2.1. Analysis by Compatible Cell Type
6.2.2. Analysis by Type of Molecule Delivered
6.3. List of Other Non-Viral Transfection System Developers
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters (Region-wise)
6.3.4. Analysis by Location of Headquarters (Country-wise)
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. Non-Viral Transfection Reagent Developers: Company Competitiveness Analysis
7.3.1. Non-Viral Transfection Reagent Developers based in North America
7.3.2. Non-Viral Transfection Reagent Developers based in Europe
7.3.3. Non-Viral Transfection Reagent Developers based in Asia-Pacific and Rest of the World
8. TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Electroporation-based Transfection Systems: Technology Competitiveness Analysis
8.3.1. Technologies Offered by Players based in North America
8.3.2. Technologies Offered by Players based in Europe
8.3.3. Technologies Offered by Players based in Asia-Pacific and Rest of the World
8.4. Other Non-Viral Transfection Systems: Technology Competitiveness Analysis
8.4.1. Technologies Offered by Players based in North America
8.4.2. Technologies Offered by Players based in Europe
8.4.3. Technologies Offered by Players based in Asia-Pacific and Rest of the World
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Non-Viral Transfection Reagent Developers
9.2.1. MilliporeSigma
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. Recent Developments and Future Outlook
9.2.2. OZ Biosciences
9.2.2.1. Company Overview
9.2.2.2. Recent Developments and Future Outlook
9.2.3. Thermo Fisher Scientific
9.2.3.1. Company Overview
9.2.3.2. Financial Information
9.2.3.3. Recent Development and Future Outlook
9.3. Electroporation-based Transfection System Developers
9.3.1. BEX
9.3.1.1. Company Overview
9.3.1.2. Recent Developments and Future Outlook
9.3.2. Bio-Rad Laboratories
9.3.2.1. Company Overview
9.3.2.2. Financial Information
9.3.2.3. Recent Developments and Future Outlook
9.3.3. BTX (A subsidiary of Harvard Bioscience)
9.3.3.1. Company Overview
9.3.3.2. Recent Developments and Future Outlook
9.3.4. MaxCyte
9.3.4.1. Company Overview
9.3.4.2. Financial Information
9.3.4.3. Recent Developments and Future Outlook
9.3.5. NepaGene
9.3.5.1. Company Overview
6.3.5.2. Recent Developments and Future Outlook
9.4. Other Non-Viral Transfection System Developers
9.4.1. Imunon (Formerly known as Celsion)
9.4.1.1. Company Overview
9.4.1.2. Recent Developments and Future Outlook
9.4.2. Genprex
9.4.2.1. Company Overview
9.4.2.2. Financial Information
9.4.2.3. Recent Developments and Future Outlook
9.4.3. Inovio Pharmaceuticals
9.4.3.1. Company Overview
9.4.3.2. Financial Information
9.4.3.3. Recent Developments and Future Outlook
10. POTENTIAL STRATEGIC PARTNERS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Non-Viral Transfection System Developers: Potential Strategic Partners in North America
10.3.1. Most Likely Partners
10.3.2. Likely Partners
10.3.3. Less Likely Partners
10.3.4. Least Likely Partners
10.4. Non-Viral Transfection System Developers: Potential Strategic Partners in Europe
10.4.1. Most Likely Partners
10.4.2. Likely Partners
10.4.3. Less Likely Partners
10.5. Non-Viral Transfection System Developers: Potential Strategic Partners in Asia-Pacific and Rest of the World
10.5.1. Most Likely Partners
10.5.2. Likely Partners
10.5.3. Less Likely Partners
11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. None-Viral Transfection Reagents and System Developers: Big Pharma Initiatives
11.3.1. Analysis by Year of Initiative
11.3.2. Analysis by Number of Initiative
11.3.3. Analysis by Type of Initiative
11.3.4. Analysis by Type of Therapy
11.3.5. Analysis by Target Therapeutic Area
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Non-Viral Transfection Reagents and Systems: Patent Analysis
12.3.1. Analysis by Publication Year
12.3.2. Analysis by Application Year
12.3.3. Analysis by Patent Jurisdiction
12.3.4. Analysis by Type of Applicant
12.3.5. Analysis by CPC Sections
12.3.6. Analysis by Emerging Focus Areas (Word Cloud Representation)
12.3.7. Leading Players: Analysis by Number of Patents
12.4. Non-Viral Transfection Reagents and Systems: Patent Benchmarking Analysis
12.4.1. Analysis by Patent Characteristics (CPC Symbols)
12.4.2. Analysis by Geography
12.5. Non-Viral Transfection Reagents and Systems: Patent Valuation Analysis
13. PUBLICATION ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Non-Viral Transfection Reagents and Systems: Recent Publications
13.4. Analysis by Year of Publication
13.5. Analysis by Type of Publication
13.6. Analysis by Type of Molecule Delivered
13.7. Analysis by Target Therapeutic Area
13.8. Analysis by Key Focus Areas (Word Cloud Representation)
13.9. Analysis by Prominent Cells and Cell Lines (Word Cloud Representation)
13.1 Leading Publishers: Analysis by Number of Publications
13.11. Prominent Journals: Analysis by Number of Publications
13.12. Prominent Copyright Holders: Analysis by Number of Publications
13.13 Key Funding Institutes: Analysis by Number of Publications
14. PRICING STRATEGY FRAMEWORK
14.1. Chapter Overview
14.2 Publisher Framework
14.2.1. Methodology
14.2.2. Theoretical Framework and Price Evaluation Hypothesis
14.2.3. Results and Interpretation
14.2.3.1. Product Price Evaluation Matrix: Based on Transfection Efficiency
14.2.3.2. Product Price Evaluation Matrix: Based on Compatible Cell Type
14.2.3.3. Product Price Evaluation Matrix: Based on Type of Carrier Used
14.2.3.4. Product Price Evaluation Matrix: Based on Type of Molecule Delivered
14.2.3.5. Product Price Evaluation Matrix: Based on Serum Compatibility
14.3. Concluding Remarks
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions
15.3. Non-Viral Transfection Reagents and Systems Market, 2023-2035
15.4. Non-Viral Transfection Reagents and Systems Market: Analysis by Type of Non-Viral Transfection Method, 2023 and 2035
15.5. Non-Viral Transfection Reagents and Systems Market: Analysis by End-User, 2023 and 2035
15.6. Non-Viral Transfection Reagents and Systems Market: Analysis by Application Area, 2023 and 2035
15.7. Non-Viral Transfection Reagents and Systems Market: Analysis by Key Geographical Regions, 2023 and 2035
15.7.1. Non-Viral Transfection Reagents and Systems Market in North America, 2023-2035
15.7.1.1. Non-Viral Transfection Reagents and Systems Market in North America: Analysis by Type of End-User, 2023-2035
15.7.1.1.1. Non-Viral Transfection Reagents and Systems Market in North America for Pharmaceutical Companies, 2023-2035
15.7.1.1.2. Non-Viral Transfection Reagents and Systems Market in North America for Academic and Research Institutions, 2023-2035
15.7.1.1.3. Non-Viral Transfection Reagents and Systems Market in North America for Other End-Users, 2023-2035
15.7.1.2. Non-Viral Transfection Reagents and Systems Market in North America: Analysis by Application Area, 2023-2035
15.7.1.2.1. Non-Viral Transfection Reagents and Systems Market in North America for Research Applications, 2023-2035
15.7.1.2.2. Non-Viral Transfection Reagents and Systems Market in North America for Clinical Applications, 2023-2035
15.7.2. Non-Viral Transfection Reagents and Systems Market in Europe, 2023-2035
15.7.2.1. Non-Viral Transfection Reagents and Systems Market in Europe: Analysis by Type of End-User, 2023-2035
15.7.2.1.1. Non-Viral Transfection Reagents and Systems Market in Europe for Pharmaceutical Companies, 2023-2035
15.7.2.1.2. Non-Viral Transfection Reagents and Systems Market in Europe for Academic and Research Institutions, 2023-2035
15.7.2.1.3. Non-Viral Transfection Reagents and Systems Market in Europe for Other End-Users, 2023-2035
15.7.2.2. Non-Viral Transfection Reagents and Systems Market in Europe: Analysis by Application Area, 2023-2035
15.7.2.2.1. Non-Viral Transfection Reagents and Systems Market in Europe for Research Applications, 2023-2035
15.7.2.2.2. Non-Viral Transfection Reagents and Systems Market in Europe for Clinical Applications, 2023-2035
15.7.3. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific, 2023-2035
15.7.3.1. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific: Analysis by Type of End-User, 2023-2035
15.7.3.1.1. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific for Pharmaceutical Companies, 2023-2035
15.7.3.1.2. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific for Academic and Research Institutions, 2023-2035
15.7.3.1.3. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific for Other End-Users, 2023-2035
15.7.3.2. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific: Analysis by Application Area, 2023-2035
15.7.3.2.1. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific for Research Applications, 2023-2035
15.7.3.2.2. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific for Clinical Applications, 2023-2035
15.7.4. Non-Viral Transfection Reagents and Systems Market in Rest of the World, 2023-2035
15.7.4.1. Non-Viral Transfection Reagents and Systems Market in Rest of the World: Analysis by Type of End-User, 2023-2035
15.7.4.1.1. Non-Viral Transfection Reagents and Systems Market in Rest of the World for Pharmaceutical Companies, 2023-2035
15.7.4.1.2. Non-Viral Transfection Reagents and Systems Market in Rest of the World for Academic and Research Institutions, 2023-2035
15.7.4.1.3. Non-Viral Transfection Reagents and Systems Market in Rest of the World for Other End-Users, 2023-2035
15.7.4.2. Non-Viral Transfection Reagents and Systems Market in Rest of the World: Analysis by Application Area, 2023-2035
15.7.4.2.1. Non-Viral Transfection Reagents and Systems Market in Rest of the World for Research Applications, 2023-2035
15.7.4.2.2. Non-Viral Transfection Reagents and Systems Market in Rest of the World for Clinical Applications, 2023-2035
16. EXECUTIVE INSIGHTS
17. CONCLUSION
18. APPENDIX I: TABULATED DATA
19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 2.1 Executive Summary: Current Landscape of Non-Viral Transfection Reagents
Figure 2.2 Executive Summary: Current Landscape of Electroporation-based Non-Viral Transfection Systems
Figure 2.3 Executive Summary: Current Landscape of Other Non-Viral Transfection Systems
Figure 2.4 Executive Summary: Big Pharma Initiatives
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Publication Analysis
Figure 2.7 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Commonly Used Viral Vectors
Figure 3.2 Types of Non-Viral Transfection Methods
Figure 3.3 Electroporation Mechanism
Figure 3.4 Gene Gun Mechanism
Figure 3.5 Sonoporation Mechanism
Figure 3.6 Microinjection Mechanism
Figure 3.7 Magnetofection Mechanism
Figure 3.8 Applications of Transfection
Figure 4.1 Non-Viral Transfection Reagents: Distribution by Type of Carrier Used
Figure 4.2 Non-Viral Transfection Reagents: Distribution by Compatible Cell Type
Figure 4.3 Non-Viral Transfection Reagents: Distribution by Type of Molecule Delivered
Figure 4.4 Non-Viral Transfection Reagents: Distribution by Serum Compatibility
Figure 4.5 Non-Viral Transfection Reagent Developers: Distribution by Year of Establishment
Figure 4.6 Non-Viral Transfection Reagent Developers: Distribution by Company Size
Figure 4.7 Non-Viral Transfection Reagent Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.8 Non-Viral Transfection Reagent Developers: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 Electroporation-based Transfection Systems: Distribution by Compatible Cell Type
Figure 5.2 Electroporation-based Transfection Systems: Distribution by Type of Molecule Delivered
Figure 5.3 Electroporation-based Transfection System Developers: Distribution by Year of Establishment
Figure 5.4 Electroporation-based Transfection System Developers: Distribution by Company Size
Figure 5.5 Electroporation-based Transfection System Developers: Distribution by Location of Headquarters (Region-wise)
Figure 5.6 Electroporation-based Transfection System Developers: Distribution by Location of Headquarters (Country-wise)
Figure 6.1 Other Non-Viral Transfection Systems: Distribution by Compatible Cell Type
Figure 6.2 Other Non-Viral Transfection Systems: Distribution by Type of Molecule Delivered
Figure 6.3 Other Non-Viral Transfection Systems: Distribution by Year of Establishment
Figure 6.4 Other Non-Viral Transfection System Developers: Distribution by Company Size
Figure 6.5 Other Non-Viral Transfection System Developers: Distribution by Location of Headquarters (Region-wise)
Figure 6.6 Other Non-Viral Transfection System Developers: Distribution by Location of Headquarters (Country-wise)
Figure 7.1 Company Competitiveness Analysis: Distribution of Non-Viral Transfection Reagent Developers based in North America
Figure 7.2 Company Competitiveness Analysis: Distribution of Non-Viral Transfection Reagent Developers based in Europe
Figure 7.3 Company Competitiveness Analysis: Distribution of Non-Viral Transfection Reagent Developers based in Asia-Pacific and Rest of the World
Figure 8.1 Electroporation-based Systems: Distribution of Technologies Offered by Players based in North America
Figure 8.2 Electroporation-based Systems: Distribution of Technologies Offered by Players based in Europe
Figure 8.3 Electroporation-based Systems: Distribution of Technologies Offered by Players based in Asia-Pacific and Rest of the World
Figure 8.4 Other Non-Viral Transfection Systems: Distribution of Technologies Offered by Players based in North America
Figure 8.5 Other Non-Viral Transfection Systems: Distribution of Technologies Offered by Players based in Europe
Figure 8.6 Other Non-Viral Transfection Systems: Distribution of Technologies Offered by Players based in Asia-Pacific and Rest of the World
Figure 9.1 MilliporeSigma: Annual Revenues, 2016-H1 2022 (USD Billion)
Figure 9.2 Thermo Fisher Scientific: Annual Revenues, 2016- H1 2022 (USD Billion)
Figure 9.3 Bio-Rad Laboratories: Annual Revenues, 2016- H1 2022 (USD Million)
Figure 9.4 MaxCyte: Annual Revenues, 2016- H1 2022 (USD Million)
Figure 9.5 Genprex: Annual Revenues, 2016- H1 2022 (USD Million)
Figure 9.6 Inovio Pharmaceuticals: Annual Revenues, 2016- H1 2022 (USD Million)
Figure 11.1 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative
Figure 11.2 Big Pharma Initiatives: Distribution by Number of Initiatives
Figure 11.3 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 11.4 Big Pharma Initiatives: Distribution by Type of Therapy
Figure 11.5 Big Pharma Initiatives: Distribution by Target Therapeutic Area
Figure 12.1 Patent Analysis: Distribution by Type of Patent
Figure 12.2 Patent Analysis: Distribution by Publication Year
Figure 12.3 Patent Analysis: Distribution by Application Year
Figure 12.4 Patent Analysis: Distribution by Patent Jurisdiction
Figure 12.5 Patent Analysis: Distribution by Type of Applicant
Figure 12.6 Patent Analysis: Distribution by CPC Sections
Figure 12.7 Word Cloud: Emerging Focus Areas
Figure 12.8 Leading Players (Industry): Distribution by Number of Patents
Figure 12.9 Leading Players (Non-Industry): Distribution by Number of Patents
Figure 12.10 Patent Benchmarking: Distribution by Patent Characteristics
Figure 12.11 Patent Analysis (Leading Industry Players): Benchmarking by CPC Symbols
Figure 12.12 Patent Analysis: Distribution by Patent Age
Figure 12.13 Non-Viral Transfection Reagents and Systems: Patent Valuation
Figure 13.1 Publication Analysis: Cumulative Year-wise Trend
Figure 13.2 Publication Analysis: Distribution by Type of Publication
Figure 13.3 Publication Analysis: Distribution by Type of Molecule Delivered
Figure 13.4 Publication Analysis: Distribution by Target Therapeutic Area
Figure 13.5 Word Cloud: Key Focus Areas
Figure 13.6 Word Cloud: Popular Cells and Cell Lines
Figure 13.7 Leading Publishers: Distribution by Number of Publications
Figure 13.8 Prominent Journals: Distribution by Number of Publications
Figure 13.9 Prominent Copyright Holders: Distribution by Number of Publications
Figure 13.10 Key Funding Institutes: Distribution by Number of Publications
Figure 14.1 Non-Viral Transfection Reagents and Systems: Pricing Strategy Framework
Figure 14.2 Non-Viral Transfection Reagents and Systems: Pricing Strategy Graphical Interpretation
Figure 15.1 Overall Non-Viral Transfection Reagents and Systems Market, 2023-2035 (USD Million)
Figure 15.2 Non-Viral Transfection Systems Market: Distribution by Type of Non-Viral Transfection Method, 2023 and 2035 (USD Million)
Figure 15.3 Non-Viral Transfection Systems Market: Distribution by End-User, 2023 and 2035 (USD Million)
Figure 15.4 Non-Viral Transfection Systems Market: Distribution by Application Area, 2023 and 2035 (USD Million)
Figure 15.5 Non-Viral Transfection Systems Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 15.6 Non-Viral Transfection Systems Market in North America, 2023-2035 (USD Million)
Figure 15.7 Non-Viral Transfection Systems Market in North America for Pharmaceutical Companies, 2023-2035 (USD Million)
Figure 15.8 Non-Viral Transfection Systems Market in North America for Academic and Research Institutions, 2023-2035 (USD Million)
Figure 15.9 Non-Viral Transfection Systems Market in North America for Other End-Users, 2023-2035 (USD Million)
Figure 15.10 Non-Viral Transfection Systems Market in North America for Research Applications, 2023-2035 (USD Million)
Figure 15.11 Non-Viral Transfection Systems Market in North America for Clinical Applications, 2023-2035 (USD Million)
Figure 15.12 Non-Viral Transfection Systems Market in Europe, 2023-2035 (USD Million)
Figure 15.13 Non-Viral Transfection Systems Market in Europe for Pharmaceutical Companies, 2023-2035 (USD Million)
Figure 15.14 Non-Viral Transfection Systems Market in Europe for Academic and Research Institutions, 2023-2035 (USD Million)
Figure 15.15 Non-Viral Transfection Systems Market in Europe for Other End-Users, 2023-2035 (USD Million)
Figure 15.16 Non-Viral Transfection Systems Market in Europe for Research Applications, 2023-2035 (USD Million)
Figure 15.17 Non-Viral Transfection Systems Market in Europe for Clinical Applications, 2023-2035 (USD Million)
Figure 15.18 Non-Viral Transfection Systems Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 15.19 Non-Viral Transfection Systems Market in Asia-Pacific for Pharmaceutical Companies, 2023-2035 (USD Million)
Figure 15.20 Non-Viral Transfection Systems Market in Asia-Pacific for Academic and Research Institutions, 2023-2035 (USD Million)
Figure 15.21 Non-Viral Transfection Systems Market in Asia-Pacific for Other End-Users, 2023-2035 (USD Million)
Figure 15.22 Non-Viral Transfection Systems Market in Asia-Pacific for Research Applications, 2023-2035 (USD Million)
Figure 15.23 Non-Viral Transfection Systems Market in Asia-Pacific for Clinical Applications, 2023-2035 (USD Million)
Figure 15.24 Non-Viral Transfection Systems Market in Rest of the World, 2023-2035 (USD Million)
Figure 15.25 Non-Viral Transfection Systems Market in Rest of the World for Pharmaceutical Companies, 2023-2035 (USD Million)
Figure 15.26 Non-Viral Transfection Systems Market in Rest of the World for Academic and Research Institutions, 2023-2035 (USD Million)
Figure 15.27 Non-Viral Transfection Systems Market in Rest of the World for Other End-Users, 2023-2035 (USD Million)
Figure 15.28 Non-Viral Transfection Systems Market in Rest of the World for Research Applications, 2023-2035 (USD Million)
Figure 15.29 Non-Viral Transfection Systems Market in Rest of the World for Clinical Applications, 2023-2035 (USD Million)
Figure 17.1. Conclusion: Current Landscape of Non-Viral Transfection Reagents
Figure 17.2 Conclusion: Current Landscape of Electroporation-based Non-Viral Transfection Systems
Figure 17.3 Conclusion: Current Landscape of Other Non-Viral Transfection Systems
Figure 17.4 Conclusion: Big Pharma Initiatives
Figure 17.5 Conclusion: Patent Analysis
Figure 17.6 Conclusion: Publication Analysis
Figure 17.7 Conclusion: Market Forecast and Opportunity Analysis
List Of Tables
Table 3.1. Specifications of Viral Vectors
Table 4.1. Non-Viral Transfection Reagents: Information on Type of Carrier Used, Compatible Cell Type and Volume of Reagent (per unit)
Table 4.2. Non-Viral Transfection Reagents: Information on Type of Molecule Delivered, Serum Compatibility and Transfection Efficiency
Table 4.3. Non-Viral Transfection Reagents: Information on Storage Temperature, Number of Transfections Per Unit Volume of Reagent and Cost of Reagent (USD)
Table 4.4. Non-Viral Transfection Reagent Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 5.1. Electroporation-based Transfection Systems: Information on Compatible Cell Type and Type of Molecule Delivered
Table 5.2. Electroporation-based Transfection Systems: Information Output Voltage, Pulse and Cost of System (USD)
Table 5.3. Electroporation-based Transfection System Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 6.1. Other Non-Viral Transfection Systems: Information on Compatible Cell Type and Type of Molecule Delivered
Table 6.2 Other Non-Viral Transfection System Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 9.1. List of Companies Profiled
Table 9.2. Altogen Biosystems: Company Snapshot
Table 9.3. Altogen Biosystems: Recent Developments and Future Outlook
Table 9.4. Millipore Sigma: Company Snapshot
Table 9.5. Millipore Sigma: Recent Developments and Future Outlook
Table 9.6. OZ Biosciences: Company Snapshot
Table 9.7. OZ Biosciences: Recent Developments and Future Outlook
Table 9.8. Thermo Fisher Scientific: Company Snapshot
Table 9.9. Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 9.10. BEX: Company Snapshot
Table 9.11. BEX: Recent Developments and Future Outlook
Table 9.12. Bio-Rad Laboratories: Company Snapshot
Table 9.13. Bio-Rad Laboratories: Recent Developments and Future Outlook
Table 9.14. BTX: Company Snapshot
Table 9.15. BTX: Recent Developments and Future Outlook
Table 9.16. MaxCyte: Company Snapshot
Table 9.17. MaxCyte: Recent Developments and Future Outlook
Table 9.18. NepaGene: Company Snapshot
Table 9.19. NepaGene: Recent Developments and Future Outlook
Table 9.20. Imunon: Company Snapshot
Table 9.21. Imunon: Recent Developments and Future Outlook
Table 9.22. Genprex: Company Snapshot
Table 9.23. Genprex: Recent Developments and Future Outlook
Table 9.24. Inovio Pharmaceuticals: Company Snapshot
Table 9.25. Inovio Pharmaceuticals: Recent Developments and Future Outlook
Table 10.1. Most Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in North America
Table 10.2. Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in North America
Table 10.3. Less Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in North America
Table 10.4. Least Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in North America
Table 10.5. Most Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Europe
Table 10.6. Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Europe
Table 10.7. Less Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Europe
Table 10.8. Most Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Asia-Pacific and Rest of the World
Table 10.9. Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Asia-Pacific and Rest of the World
Table 10.10. Less Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Asia-Pacific and Rest of the World
Table 11.1. Big Pharma Initiatives: List of Non-Viral Transfection Focused Initiatives
Table 12.1. Patent Analysis: Top CPC Sections
Table 12.2. Patent Analysis: Top CPC Symbols
Table 12.3. Patent Analysis: Top CPC Codes
Table 12.4. Patent Analysis: Summary of Benchmarking Analysis
Table 12.5. Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 14.1. Product Price Evaluation Matrix: Based on Transfection Efficiency
Table 14.2. Product Price Evaluation Matrix: Based on Compatible Cell Type
Table 14.3. Product Price Evaluation Matrix: Based on Type of Carrier Used
Table 14.4. Product Price Evaluation Matrix: Based on Type of Molecule Delivered
Table 14.5. Product Price Evaluation Matrix: Based on Serum Compatibility
Table 18.1. Non-Viral Transfection Reagents: Distribution by Type of Carrier Used
Table 18.2. Non-Viral Transfection Reagents: Distribution by Compatible Cell Type
Table 18.3. Non-Viral Transfection Reagents: Distribution by Type of Molecule Delivered
Table 18.4. Non-Viral Transfection Reagents: Distribution by Serum Compatibility
Table 18.5. Non-Viral Transfection Reagent Developers: Distribution by Year of Establishment
Table 18.6. Non-Viral Transfection Reagent Developers: Distribution by Company Size
Table 18.7. Non-Viral Transfection Reagent Developers: Distribution by Location of Headquarters (Region-wise)
Table 18.8. Non-Viral Transfection Reagent Developers: Distribution by Location of Headquarters (Country-wise)
Table 18.9. Electroporation-based Transfection Systems: Distribution by Compatible Cell Type
Table 18.10. Electroporation-based Transfection Systems: Distribution by Type of Molecule Delivered
Table 18.11. Electroporation-based Transfection System Developers: Distribution by Year of Establishment
Table 18.12. Electroporation-based Transfection System Developers: Distribution by Company Size
Table 18.13. Electroporation-based Transfection System Developers: Distribution by Location of Headquarters (Region-wise)
Table 18.14. Electroporation-based Transfection System Developers: Distribution by Location of Headquarters (Country-wise)
Table 18.15. Other Non-Viral Transfection Systems: Distribution by Compatible Cell Type
Table 18.16. Other Non-Viral Transfection Systems: Distribution by Type of Molecule Delivered
Table 18.17. Other Non-Viral Transfection Systems: Distribution by Year of Establishment
Table 18.18. Other Non-Viral Transfection System Developers: Distribution by Company Size
Table 18.19. Other Non-Viral Transfection System Developers: Distribution by Location of Headquarters (Region-wise)
Table 18.20. Other Non-Viral Transfection System Developers: Distribution by Location of Headquarters (Country-wise)
Table 18.21 MilliporeSigma: Annual Revenues, 2016-H1 2022 (USD Billion)
Table 18.22 Thermo Fisher Scientific: Annual Revenues, 2016- H1 2022 (USD Billion)
Table 18.23 Bio-Rad Laboratories: Annual Revenues, 2016- H1 2022 (USD Million)
Table 18.24 MaxCyte: Annual Revenues, 2016- H1 2022 (USD Million)
Table 18.25 Genprex: Annual Revenues, 2016- H1 2022 (USD Million)
Table 18.26 Inovio Pharmaceuticals: Annual Revenues, 2016- H1 2022 (USD Million)
Table 18.27 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative
Table 18.28 Big Pharma Initiatives: Distribution by Number of Initiatives
Table 18.29 Big Pharma Initiatives: Distribution by Type of Initiative
Table 18.30 Big Pharma Initiatives: Distribution by Type of Therapy
Table 18.31 Big Pharma Initiatives: Distribution by Target Therapeutic Area
Table 18.32 Patent Analysis: Distribution by Type of Patent
Table 18.33 Patent Analysis: Distribution by Publication Year
Table 18.34 Patent Analysis: Distribution by Application Year
Table 18.35 Patent Analysis: Distribution by Patent Jurisdiction
Table 18.36 Patent Analysis: Distribution by Type of Applicant
Table 18.37 Patent Analysis: Distribution by CPC Sections
Table 18.38 Leading Players (Industry): Distribution by Number of Patents
Table 18.39 Leading Players (Non-Industry): Distribution by Number of Patents
Table 18.40 Patent Benchmarking: Distribution by Patent Characteristics
Table 18.41 Patent Analysis (Leading Industry Players): Benchmarking by CPC Symbols
Table 18.42 Patent Analysis: Distribution by Patent Age
Table 18.43 Non-Viral Transfection Reagents and Systems: Patent Valuation
Table 18.44 Publication Analysis: Cumulative Year-wise Trend
Table 18.45 Publication Analysis: Distribution by Type of Publication
Table 18.46 Publication Analysis: Distribution by Type of Molecule Delivered
Table 18.47 Publication Analysis: Distribution by Target Therapeutic Area
Table 18.48 Leading Publishers: Distribution by Number of Publications
Table 18.49 Prominent Journals: Distribution by Number of Publications
Table 18.50 Prominent Copyright Holders: Distribution by Number of Publications
Table 18.51 Key Funding Institutes: Distribution by Number of Publications
Table 18.52 Overall Non-Viral Transfection Reagents and Systems Market, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.53 Non-Viral Transfection Systems Market, Conservative, Base and Optimistic Scenario: Distribution by Type of Non-Viral Transfection Method, 2023 and 2035 (USD Million)
Table 18.54 Non-Viral Transfection Systems Market, Conservative, Base and Optimistic Scenario: Distribution by End-User, 2023 and 2035 (USD Million)
Table 18.55 Non-Viral Transfection Systems Market, Conservative, Base and Optimistic Scenario: Distribution by Application Area, 2023 and 2035 (USD Million)
Table 18.56 Non-Viral Transfection Systems Market, Conservative, Base and Optimistic Scenario: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 18.57 Non-Viral Transfection Systems Market in North America, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.58 Non-Viral Transfection Systems Market in North America for Pharmaceutical Companies, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.59 Non-Viral Transfection Systems Market in North America for Academic and Research Institutions, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.60 Non-Viral Transfection Systems Market in North America for Other End-Users, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.61 Non-Viral Transfection Systems Market in North America for Research Applications, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.62 Non-Viral Transfection Systems Market in North America for Clinical Applications, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.63 Non-Viral Transfection Systems Market in Europe, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.64 Non-Viral Transfection Systems Market in Europe for Pharmaceutical Companies, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.65 Non-Viral Transfection Systems Market in Europe for Academic and Research Institutions, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.66 Non-Viral Transfection Systems Market in Europe for Other End-Users, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.67 Non-Viral Transfection Systems Market in Europe for Research Applications, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.68 Non-Viral Transfection Systems Market in Europe for Clinical Applications, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.69 Non-Viral Transfection Systems Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.70 Non-Viral Transfection Systems Market in Asia-Pacific for Pharmaceutical Companies, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.71 Non-Viral Transfection Systems Market in Asia-Pacific for Academic and Research Institutions, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.72 Non-Viral Transfection Systems Market in Asia-Pacific for Other End-Users, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.73 Non-Viral Transfection Systems Market in Asia-Pacific for Research Applications, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.74 Non-Viral Transfection Systems Market in Asia-Pacific for Clinical Applications, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.75 Non-Viral Transfection Systems Market in Rest of the World, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.76 Non-Viral Transfection Systems Market in Rest of the World for Pharmaceutical Companies, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.77 Non-Viral Transfection Systems Market in Rest of the World for Academic and Research Institutions, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.78 Non-Viral Transfection Systems Market in Rest of the World for Other End-Users, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.79 Non-Viral Transfection Systems Market in Rest of the World for Research Applications, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 18.80 Non-Viral Transfection Systems Market in Rest of the World for Clinical Applications, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4basebio
- AAT Bioquest
- Applied Biological Materials (abm)
- Advaxis
- Agilent Technologies
- Allergan
- Almirall
- American Society of Gene & Cell Therapy (ASGCT)
- Anaeropharma Science
- AnGes
- Anjarium Biosciences
- Astellas Pharma
- AstraZeneca
- ATCC
- Beam Therapeutics
- BEX
- Bio Basic
- BioMarin Pharmaceutical
- Biomaterials USA
- BioMed Central
- Biontex Laboratories
- Biopact Ventures
- Bio-Rad Laboratories
- BioTools
- Broad Institute
- Eterna Therapeutics (formerly known as Brooklyn ImmunoTherapeutics)
- BTX (A subsidiary of Harvard Bioscience)
- Canvax
- Carmine Therapeutics
- Cartesian Therapeutics
- Celetrix
- Cell and Gene Therapy Catapult
- Cell Applications
- CellFE
- Imunon (Formerly known as Celsion)
- Charles Stark Draper Laboratory
- China Postdoctoral Science Foundation
- Chinese PLA General Hospital
- Clearside Biomedical
- Code Biotherapeutics
- Copernicus Therapeutics
- Cosmo Bio
- Creative Biolabs
- CRISPR Therapeutics
- CureVac
- CyGenica
- Cystic Fibrosis Foundation
- DARPA
- DNAlite Therapeutics
- Drummond Scientific
- Eden BioCell
- Eli Lilly
- Elsevier
- ENDOSCAPE
- enGene
- Ensoma
- Entos Pharmaceuticals
- Enzo Life Sciences
- European Commission
- European Research Council
- Seventh Framework Programme
- Eterna Therapeutics
- Evox Therapeutics
- Exicure
- Eyevensys
- EZ Biosystems
- FormuMax Scientific
- Fred Hutchinson Cancer Research Center
- Frontiers Media
- GeminiBio
- GeneCopoeia
- GeneDireX
- GenEdit
- GeneOne Life Science
- Generation Bio
- Genexine
- Genlantis
- Gennao Bio
- Genprex
- Gilead Sciences
- GlaxoSmithKline Biologicals
- GOG Foundation
- Gradalis
- Guangzhou Medical University
- H. Lee Moffitt Cancer Center and Research Institute
- Harvard Medical School
- Helixmith
- Horizon Discovery
- Human Stem Cells Institute PJSC (HSCI)
- HIV Vaccine Trials Network (HVTN)
- Icosagen
- Ilya Pharma
- Immudicon
- IMUNON
- In-Cell-Art
- indee labs
- Inovio Pharmaceuticals
- National Institute of Health and Medical Research (INSERM)
- Intellia Therapeutics
- iNtRON Biotechnology
- InvivoGen
- Johns Hopkins Kimmel Cancer Center
- Johnson & Johnson
- Kodikaz Therapeutic Solutions
- Kytopen
- Lemonex
- Lion TCR
- Locate Bio
- Lonza
- Massachusetts Eye and Ear
- Massachusetts Institute of Technology (MIT)
- MaxCyte
- Massachusetts College of Pharmacy and Health Sciences (MCPHS)
- MDPI
- Memorial Sloan Kettering Cancer Center
- Merck KGaA
- Mekonos
- Metagenomi
- MilliporeSigma
- Miltenyi Biotech
- Mirus Bio
- Moderna
- N4 Pharma
- Nanoscope Therapeutics
- National Cancer Institute
- National Health and Medical Research Council
- National Institute of Health
- National Natural Science Foundation of China
- National Science Foundation
- Nature Publishing Group
- NAVAN Technologies
- Nepa Gene
- Neuromics
- NHGRI
- NIAID
- Novo Nordisk
- Obschestvo S Ogranichennoi Otvetstvennostju Proryvnye Innovatsionnye Tekh
- Oisin Biotechnologies
- OncoSec Immunotherapies
- OncoSenX
- OpenCell Technologies
- OrganoLinX
- OriGene
- OZ Biosciences
- Pfizer
- pHion Therapeutics
- PhorMed
- Polyplus-transfection
- Polysciences
- Pontificia Universidad Javeriana
- Poseida Therapeutics
- Precigen
- Precision Bio Laboratories
- Precision BioSciences
- Precision Nanosystems
- Promega
- Proteacel
- Public Library of Science (PLOS)
- QIAGEN
- Redbiotec
- Reyon Pharmaceutical
- RJH Biosciences
- Roche
- Ruijin Hospital
- Sanofi
- Santa Cruz Biotechnology
- Scancell
- ScreenFect
- Second Affiliated Hospital of Guangzhou Medical University
- Shanghai Bioray Laboratory
- SignaGen Laboratories
- Sino Biological
- SiSaf
- SparingVision
- SQZ Biotechnologies
- Stanford University
- STRM.BIO
- Sutter Instrument
- Synvolux
- System Biosciences
- Takara Bio
- Takeda
- Tecrea
- The Royal Society of Chemistry
- Thermo Fisher Scientific
- T-Pro Biotechnology
- Translate Bio
- Transomic Technologies
- Tritech Research
- Tyris Therapeutics
- U.S. Department of Defense
- University of California
- University of Minnesota
- University of Pennsylvania
- Urovant Sciences
- Us Health
- Wellcome Trust
- Westburg Life Sciences
- Wize Pharma
- University Hospital Wuerzburg
- Yeasen Biotechnology
- Xalud Therapeutics
- Zhejiang University
Methodology
LOADING...
